Compare Quest Diagnostics Inc (DGX) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Dicks Sporting Goods Inc — how do they compare? Quest Diagnostics Inc trades at $231.26 (market cap $25.48B), while Dicks Sporting Goods Inc trades at $136.27 (market cap $13.26B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Dicks Sporting Goods Inc pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Dicks Sporting Goods Inc for 19 Days on average.
| DGX | DKS | |
|---|---|---|
Market Cap | $25.48B | $13.26B |
Volume | 941,866 | 2,292,035 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $239.17 |
52-Week Low | $173.49 | $121.15 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | $31.23B | $20.31B |
Dividend Yield | 1.49% | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
DICK'S Sporting Goods (DKS) trades at $135.99, up 3.67% today, with a bearish technical signal but strong fundamentals including a P/E of 14.86 and ROE of 18.47%. Recent earnings show mixed results, with a Q2 2026 miss, while revenue grew to $13.44B in 2025. The stock faces headwinds from a securities class action lawsuit, but analysts maintain a buy consensus with a $153.30 price target.
The outlook is cautious due to legal risks and a bearish technical trend, but solid profitability and valuation metrics offer support. Upside potential exists if legal issues resolve and earnings rebound, though investor sentiment is tempered by near-term uncertainties. Risks include litigation outcomes and competitive pressures in retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
